Full Press Release Details
Announces Distribution Agreement
for CGuardTM EPS in Germany
Aviv-May 1, 2017 - InspireMD, Inc. (NYSE MKT:NSPR) (NYSE MKT:NSPR.WS) ("InspireMD" or the "Company"),
a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it
has signed an agreement with ab medica Deutschland GmbH & Co. KG, ("ab medica GmbH") a leading medical distributor
in Germany, to distribute CGuard EPS (Embolic Prevention System).
Barry, PhD, Chief Executive Officer of InspireMD, commented, "ab medica GmbH is probably the leading distributor in the
peripheral and vascular medical devices sector in Germany and this agreement is consistent with our new strategy of utlizing a
direct distribution model focusing on regional distributors that have access to all of the key clinical specialties. Germany is
the largest CAS market in Europe and, given the strong growth we saw in 2016 in the markets where this model has been in place
and managed by InspireMD, we are very optimistic about the market potential for our product in Germany."
Georg Landsberg, CEO & Founder of ab medica GmbH, stated, "We are excited to partner with InspireMD to distribute CGuard
in Germany. We are committed to building on the work done by InspireMD's prior distributor in Germany and adding at least
50 new hospitals to our client list and thus more than doubling CGuard's market presence and market share over the next
twelve months. Our ability to include as yet untapped markets such as the Vascular Surgery segment in our sales efforts, makes
us confident that we can add a new dynamic to the markerting of CGuard, which we believe will rapidly become the standard of care
through its potential safety benefits.
Gago, EVP and Chief Commercial Officer of InspireMD, noted, "ab medica GmbH is an ideal partner as it has long standing
relations with all the major Group Purchasing Organizations in Germany covering all the relevant clinical specialists that use
carotid stents. ab medica also has established relationships with Germany's top KOLs, including interventional neuroradiologists,
vascular surgeons, interventional cardiologists and interventional radiologists. ab medica will immediateliy assume all the existing
accounts supported by our former distributor, with plans to at least double the number of centers utilizing our device in Germany
over the next year."
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR and certain warrants
are quoted on the NYSE MKT under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.